Amriti R. Lulla

897 citations

24 papers · 434 indexed · h-index 11

Co-authors: Wafik S. El‐Deiry David T. Dicker Joshua E. Allen Marie D. Ralff Avital Lev C. Leah B. Kline Jessica Wagner Varun V. Prabhu
Topics: Cancer-related Molecular Pathways (9 papers)Cancer therapeutics and mechanisms (4 papers)Cell death mechanisms and regulation (4 papers)
Cited by: Cancer Research Oncology Molecular Biology
Journals: Blood PLoS ONE Cancer Research
Partner nations: United States United Kingdom France

In The Last Decade

Amriti R. Lulla

21 papers receiving 431 citations

Peers

Countries citing papers authored by Amriti R. Lulla

Since Specialization

Citations

This map shows the geographic impact of Amriti R. Lulla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amriti R. Lulla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amriti R. Lulla more than expected).

Fields of papers citing papers by Amriti R. Lulla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amriti R. Lulla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amriti R. Lulla. The network helps show where Amriti R. Lulla may publish in the future.

Co-authorship network of co-authors of Amriti R. Lulla

This figure shows the co-authorship network connecting the top 25 collaborators of Amriti R. Lulla. A scholar is included among the top collaborators of Amriti R. Lulla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amriti R. Lulla. Amriti R. Lulla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Low–Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer 2024 ·Cancer Research ·Mi Li,Amriti R. Lulla,(unknown),Spyros Tsavachidis,(unknown),Cansu Karakaş,Tuyen Duong Thanh Nguyen,Tuyen Bui,(unknown),Mei‐Kuang Chen,Sofia Mastoraki,Asha S. Multani,Natalie W. Fowlkes,Ayşegül A. Şahin,(unknown),Kelly K. Hunt,Khandan Keyomarsi	4
2	Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis 2023 ·Molecular Cancer Therapeutics ·Amriti R. Lulla,Saïd Akli,Cansu Karakaş,(unknown),(unknown),Natalie W. Fowlkes,Xiayu Rao,Jing Wang,Kelly K. Hunt,Stephanie S. Watowich,Khandan Keyomarsi	10
3	Abstract 950: Targeting PKMYT1 kinase is an effective treatment strategy in triple negative breast cancers with low molecular weight cyclin E (LMW-E) expression 2023 ·Cancer Research ·Amriti R. Lulla,Tuyen Duong Thanh Nguyen,Mi Li,Sofia Mastoraki,Yan Wang,Tuyen Bui,(unknown),Spiridon Tsavachidis,Gary S. Marshall,Kelly K. Hunt,Khandan Keyomarsi	3
4	Abstract 2592: Aurora kinase is an actionable target in low molecular weight cyclin E induced mammary tumors 2022 ·Cancer Research ·Saïd Akli,Amriti R. Lulla,(unknown),(unknown),Natalie W. Fowlkes,Tuyen Bui,Yan Wang,Sofia Mastoraki,Min Jin Ha,Kelly K. Hunt,Khandan Keyomarsi	1
5	miR-3132 upregulates surface TRAIL to induce apoptotic cell death in cancer cells. 2022 ·PubMed ·Amriti R. Lulla,Yan Zhou,Marie D. Ralff,Avital Lev,David T. Dicker,Wafik S. El‐Deiry	2
6	P53-independent partial restoration of the p53 pathway in tumors with mutated p53 through ATF4 transcriptional modulation by ERK1/2 and CDK9 2021 ·Neoplasia ·Xiaobing Tian,Nagib Ahsan,Amriti R. Lulla,Avital Lev,Philip H. Abbosh,David T. Dicker,Shengliang Zhang,Wafik S. El‐Deiry	17
7	ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer 2018 ·Molecular Cancer Research ·Avital Lev,Amriti R. Lulla,Brian C. Ross,Marie D. Ralff,(unknown),David T. Dicker,Wafik S. El‐Deiry	22
8	miR-6883 Family miRNAs Target CDK4/6 to Induce G1 Phase Cell-Cycle Arrest in Colon Cancer Cells 2017 ·Cancer Research ·Amriti R. Lulla,Michael Slifker,Yan Zhou,Avital Lev,Margret B. Einarson,David T. Dicker,Wafik S. El‐Deiry	44
9	Role of Dopamine Receptors in the Anticancer Activity of ONC201 2017 ·Neoplasia ·C. Leah B. Kline,Marie D. Ralff,Amriti R. Lulla,Jessica Wagner,Philip H. Abbosh,David T. Dicker,Joshua E. Allen,Wafik S. El‐Deiry	94
10	Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors 2017 ·PLoS ONE ·Varun V. Prabhu,Amriti R. Lulla,Neel S. Madhukar,Marie D. Ralff,Dan Zhao,C. Leah B. Kline,A. Pieter J. van den Heuvel,Avital Lev,Mathew J. Garnett,Ultan McDermott,Cyril H. Benes,Tracy T. Batchelor,S. Andrew,Olivier Elemento,Joshua E. Allen,Wafik S. El‐Deiry	30
11	Abstract 5455: Novel miRNA-based therapeutic approach to selectively target mutant p53 in cancer 2017 ·Cancer Research ·Amriti R. Lulla,Margret B. Einarson,Yan Zhou,David T. Dicker,Wafik S. El‐Deiry	1
12	CB002, a novel p53 tumor suppressor pathway-restoring small molecule induces tumor cell death through the pro-apoptotic protein NOXA 2017 ·Cell Cycle ·(unknown),Shengliang Zhang,Amriti R. Lulla,David T. Dicker,Wafik S. El‐Deiry	9
13	Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212 2017 ·Cell Cycle ·Jessica Wagner,C. Leah B. Kline,Marie D. Ralff,Avital Lev,Amriti R. Lulla,Lanlan Zhou,Gary L. Olson,(unknown),Cyril H. Benes,Joshua E. Allen,Varun V. Prabhu,Martin Stogniew,Wolfgang Oster,Wafik S. El‐Deiry	56
14	Abstract 1067: Anti-cancer efficacy of imipridones in pancreatic cancer: single agent ONC212 or combination of ONC201 with IGF1-R inhibition 2017 ·Cancer Research ·Avital Lev,Amriti R. Lulla,Jessica Wagner,David T. Dicker,Wafik S. El‐Deiry	1
15	Preclinical rationale for combination of crizotinib with mitomycin C for the treatment of advanced colorectal cancer 2017 ·Cancer Biology & Therapy ·Avital Lev,Safoora Deihimi,Elena Shagisultanova,Joanne Xiu,Amriti R. Lulla,David T. Dicker,Wafik S. El‐Deiry	14
16	Abstract 2102: ONC201 targets AR and AR-V7 signaling pathways, reduces PSA and synergizes with everolimus in castration resistant prostate cancer 2017 ·Cancer Research ·Avital Lev,Amriti R. Lulla,David T. Dicker,Wafik S. El‐Deiry	1
17	Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP 2017 ·Oncotarget ·Avital Lev,Amriti R. Lulla,Jessica Wagner,Marie D. Ralff,(unknown),Yan Zhou,Cyril H. Benes,Varun V. Prabhu,Wolfgang Oster,Igor Astsaturov,David T. Dicker,Wafik S. El‐Deiry	37
18	Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies 2017 ·Cell Cycle ·Varun V. Prabhu,Mala K. Talekar,Amriti R. Lulla,C. Leah B. Kline,Lanlan Zhou,Junior Hall,A. Pieter J. van den Heuvel,David T. Dicker,(unknown),Stephan A. Grupp,Mathew J. Garnett,Ultan McDermott,Cyril H. Benes,Jeffrey J. Pu,David F. Claxton,Nadia Khan,Wolfgang Oster,Joshua E. Allen,Wafik S. El‐Deiry	33
19	Small-Molecule Prodigiosin Restores p53 Tumor Suppressor Activity in Chemoresistant Colorectal Cancer Stem Cells via c-Jun-Mediated ΔNp73 Inhibition and p73 Activation 2016 ·Cancer Research ·Varun V. Prabhu,Bo Hong,Joshua E. Allen,Shengliang Zhang,Amriti R. Lulla,David T. Dicker,Wafik S. El‐Deiry	49
20	Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins 2014 ·Blood ·Varun V. Prabhu,Amriti R. Lulla,Jessica Wagner,(unknown),Mala K. Talekar,C. Leah B. Kline,David T. Dicker,Brian M. Barth,Jeffrey J. Pu,David F. Claxton,Joshua E. Allen,Wafik S. El‐Deiry	0

About Amriti R. Lulla

Amriti R. Lulla is a scholar working on Applied Microbiology and Biotechnology, Oncology and Cancer Research, having authored 24 papers that have together received 434 indexed citations. Recurring topics across this work include Cancer-related Molecular Pathways (9 papers), Cancer therapeutics and mechanisms (4 papers) and Cell death mechanisms and regulation (4 papers). The work is most often cited by research in Cancer Research (97 citations), Oncology (135 citations) and Molecular Biology (277 citations). Amriti R. Lulla has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Wafik S. El‐Deiry, David T. Dicker, Joshua E. Allen, Marie D. Ralff, Avital Lev, C. Leah B. Kline, Jessica Wagner, Varun V. Prabhu, Philip H. Abbosh and Cyril H. Benes. Their work appears in journals such as Blood, PLoS ONE and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact